Amedeo Smart

Free Medical Literature Service

 

Amedeo

Tuberculosis
  Free Subscription

Articles published in
Emerg Infect Dis
    December 2025
  1. KURBATOVA EV, Whitworth WC, Bryant KE, Dixon MG, et al
    Pregnancy Outcomes after Exposure to Tuberculosis Treatment in Phase 3 Clinical Trial, 2016-2020.
    Emerg Infect Dis. 2025;31:2233-2242.
    >> Share

    November 2025
  2. SEUNG KJ, Asfaw M, Kunda M, Maama-Maime LB, et al
    Extensively Drug-Resistant Tuberculosis with Conflicting Resistance Testing Results, Lesotho.
    Emerg Infect Dis. 2025;31:2185-2187.
    >> Share

    October 2025
  3. GUO C, Pan Y, Yu J, Yao L, et al
    Disseminated Blastomycosis Mimicking Tuberculosis, China.
    Emerg Infect Dis. 2025;31:2046-2048.
    >> Share

    July 2025
  4. ROY A, Gomez-Barroso D, Cruz-Ferro E, Fernandez A, et al
    Spatiotemporal Distribution and Clinical Characteristics of Zoonotic Tuberculosis, Spain, 2018-2022.
    Emerg Infect Dis. 2025;31:1344-1352.
    >> Share

  5. ASAY GRB, Young KH, Hill TD, Njie GJ, et al
    Systematic Review of Contact Investigation Costs for Tuberculosis, United States.
    Emerg Infect Dis. 2025;31:1284-1293.
    >> Share

    March 2025
  6. PAUL R, Lorenzo F, Lopez B, Alegre MG, et al
    Outbreak Caused by Multidrug-Resistant Mycobacterium Tuberculosis with Unusual Combination of Resistance Mutations, Northern Argentina, 2006-2022.
    Emerg Infect Dis. 2025;31:601-606.
    >> Share

  7. KLINKENBERG E, de Haas P, Manyonge C, Namutebi J, et al
    Lessons Learned from Early Implementation and Scale-up of Stool-Based Xpert Testing to Diagnose Tuberculosis in Children.
    Emerg Infect Dis. 2025;31:1-9.
    >> Share

  8. GERUSSI V, Petersen T, Bonnet I, Aubry A, et al
    Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment.
    Emerg Infect Dis. 2025;31:633-636.
    >> Share

  9. FRANCISCO NM, Gaviraghi A, Alladio F, Huits R, et al
    Multidrug-Resistant Mycobacterium tuberculosis in a Community Hospital, Luanda, Angola.
    Emerg Infect Dis. 2025;31:627-629.
    >> Share

  10. KONSTANTYNOVSKA O, Synenko T, Honcharenko A, Volobuieva O, et al
    Fluoroquinolone Resistance in Drug-Resistant Tuberculosis, Kharkiv, Ukraine, 2019-2023.
    Emerg Infect Dis. 2025;31:615-617.
    >> Share

  11. JUNG E, Alarcon VA, Solis Tupes WS, Avalos-Cruz T, et al
    National Active Case-Finding Program for Tuberculosis in Prisons, Peru, 2024.
    Emerg Infect Dis. 2025;31:564-568.
    >> Share

  12. SHRESTHA S, Cilloni L, Asay GRB, Kammerer JS, et al
    Model-Based Analysis of Impact, Costs, and Cost-effectiveness of Tuberculosis Outbreak Investigations, United States.
    Emerg Infect Dis. 2025;31:497-506.
    >> Share

  13. ZIMENKOV D, Ushtanit A, Gordeeva E, Guselnikova E, et al
    High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia.
    Emerg Infect Dis. 2025;31:525-536.
    >> Share

  14. KURBATOVA EV, Whitworth WC, Peddareddy LP, Phillips PPJ, et al
    Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.
    Emerg Infect Dis. 2025;31:467-476.
    >> Share

    November 2024
  15. GORVETZIAN S, Pacheco AG, Anderson E, Ray SM, et al
    Mortality Rates after Tuberculosis Treatment, Georgia, USA, 2008-2019.
    Emerg Infect Dis. 2024;30:2261-2270.
    >> Share

    August 2024
  16. MCQUAID CF, Ryckman TS, Menzies NA, White RG, et al
    Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance.
    Emerg Infect Dis. 2024;30:1571-1579.
    >> Share

    July 2024
  17. LUKOYE D, Kalamya JN, Awor AC, Gustavson G, et al
    Treatment Outcomes for Tuberculosis Infection and Disease Among Persons Deprived of Liberty, Uganda, 2020.
    Emerg Infect Dis. 2024;30:1402-1405.
    >> Share

    June 2024
  18. TAN Q, Huang CC, Becerra MC, Calderon R, et al
    Chest Radiograph Screening for Detecting Subclinical Tuberculosis in Asymptomatic Household Contacts, Peru.
    Emerg Infect Dis. 2024;30:1115-1124.
    >> Share

    April 2024
  19. FUKUNAGA R, Pierre P, Williams JK, Briceno-Robaugh R, et al
    Prioritizing Mental Health within HIV and Tuberculosis Services in PEPFAR.
    Emerg Infect Dis. 2024;30:1-5.
    >> Share

  20. DAHL VN, Butova T, Rosenthal A, Grinev A, et al
    Drug-Resistant Tuberculosis, Georgia, Kazakhstan, Kyrgyzstan, Moldova, and Ukraine, 2017-2022.
    Emerg Infect Dis. 2024;30:831-833.
    >> Share

  21. GURREY SO, Strick LB, Dov LK, Miller JS, et al
    Lessons Learned from Public Health and State Prison Collaborations during COVID-19 Pandemic and Multifacility Tuberculosis Outbreak, Washington, USA.
    Emerg Infect Dis. 2024;30:S17-S20.
    >> Share

    March 2024
  22. SPIES R, Hong HN, Trieu PP, Lan LK, et al
    Spatial Analysis of Drug-Susceptible and Multidrug-Resistant Cases of Tuberculosis, Ho Chi Minh City, Vietnam, 2020-2023.
    Emerg Infect Dis. 2024;30:499-509.
    >> Share

  23. GUNTHER G, Mhuulu L, Diergaardt A, Dreyer V, et al
    Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.
    Emerg Infect Dis. 2024;30:568-571.
    >> Share

    January 2024
  24. HAN E, Nabity SA, Dasgupta-Tsinikas S, Guevara RE, et al
    Tuberculosis Diagnostic Delays and Treatment Outcomes among Patients with COVID-19, California, USA, 2020.
    Emerg Infect Dis. 2024;30:136-140.
    >> Share

  25. HUMAYUN M, Mukasa L, Ye W, Bates JH, et al
    Racial and Ethnic Disparities in Tuberculosis Incidence, Arkansas, USA, 2010-2021.
    Emerg Infect Dis. 2024;30:116-124.
    >> Share

  26. NSENGIYUMVA NP, Khan A, Gler MMTS, Tonquin ML, et al
    Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018-2021.
    Emerg Infect Dis. 2024;30:79-88.
    >> Share

    December 2023
  27. LAFLEUR M, Rasoanaivo HA, Andrianarivo TH, Andrianomanana FR, et al
    Tuberculosis in Lemurs and a Fossa at National Zoo, Madagascar, 2022.
    Emerg Infect Dis. 2023;29:2587-2589.
    >> Share

    November 2023
  28. MODONGO C, Barilar I, Wang Q, Molefi T, et al
    Tuberculosis Variant with Rifampin Resistance Undetectable by Xpert MTB/RIF, Botswana.
    Emerg Infect Dis. 2023;29:2403-2406.
    >> Share

    October 2023
  29. WINSTON CA, Marks SM, Carr W
    Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States.
    Emerg Infect Dis. 2023;29:2102-2104.
    >> Share

    August 2023
  30. NABITY SA, Marks SM, Goswami ND, Smith SR, et al
    Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States.
    Emerg Infect Dis. 2023;29.
    >> Share

  31. LOUIE JK, Agraz-Lara R, Romo L, Deiterich C, et al
    Uniting for Ukraine Tuberculosis Screening Experience, San Francisco, California, USA.
    Emerg Infect Dis. 2023;29:1651-1654.
    >> Share

    July 2023
  32. WOODRUFF R, Miramontes R
    Tuberculosis Infection among Non-US-Born Persons and Persons >/=60 Years of Age, United States, 2019-2020.
    Emerg Infect Dis. 2023;29:1470-1472.
    >> Share

    May 2023
  33. NOROC E, Chesov D, Merker M, Groschel MI, et al
    Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova.
    Emerg Infect Dis. 2023;29:1046-1050.
    >> Share

  34. NGUYEN HV, Brals D, Tiemersma E, Gasior R, et al
    Influence of Sex and Sex-Based Disparities on Prevalent Tuberculosis, Vietnam, 2017-2018.
    Emerg Infect Dis. 2023;29:967-976.
    >> Share

  35. BAKER CR, Barilar I, de Araujo LS, Rimoin AW, et al
    Use of High-Resolution Geospatial and Genomic Data to Characterize Recent Tuberculosis Transmission, Botswana.
    Emerg Infect Dis. 2023;29:977-987.
    >> Share

  36. MILLARD J, Rimmer S, Nimmo C, O'Donnell M, et al
    Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
    Emerg Infect Dis. 2023;29:1081-1084.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016